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Abstract
Background: In spite of effective therapy, tuberculosis (TB) is still a major health problem in developing countries. In 1993, therefore, 
the World Health Organization declared TB a global emergency. In South Africa, TB is one of the most prevalent diseases, with an 
incidence of 556 per 100 000 population. In spite of free TB drugs in the public service and the directly observed treatment short 
course (DOTS) strategies, there is still a high prevalence of TB and a high treatment interruption rate in rural South Africa.
Methods: The objectives of this study were to establish the prevalence of TB and reasons for the interruption of TB treatment by 
patients attending Mbekweni Health Centre in King Sabata Dalidyebo (KSD) district in the Eastern Cape province. This was a cross-
sectional study in which data were collected from 15 July 2004 to 15 January 2005 from patients who were on TB treatment and 
interrupted their treatment between 6 August 2001 and 30 December 2003. 
Results: Of the 255 TB patients who attended for treatment, 121 (47.5%) had interrupted their treatment. Reasons given for interrup-
tion included change of living place (18.96%), no money to go to the clinic (15.52%), feeling better (13.78%), side effects of the drug 
(6.90%), did not know the treatment course (5.17%), physical disability  either old or too sick to collect treatment and nobody to help 
(5.17%), clinic too far (1.73%), drug not available in the clinic (13.83%) and no reasons (8.62%).
Conclusion: The prevalence of treatment interruption was high in this study. Change of living place, lack of money for visiting the 
clinic to collect treatment, feeling better, and no drugs at the clinic were the major reasons given for interruption of treatment. Ensuring 
the availability of TB drugs at the health centre/clinic, patient education about TB and strengthening the DOTS programme, including 
a stipend for the DOTS supervisors, would help to reduce the prevalence of treatment interruption.
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(6):47
SA Fam Pract 2008                  Vol 50 No 647a
Original Research
Introduction
In 1993, the World Health Organization (WHO) declared tuberculosis 
(TB) a global emergency because it kills more adults each year than 
any other infectious disease.1 TB accounts for 1.6 million deaths 
annually.2 Despite large efforts in the field of mycobacterium TB 
research over the past few decades, little progress has been made 
in the development of novel chemotherapeutic agents. However, the 
availability of the genome sequence has led to the identification and 
characterisation of potential drug targets for this pathogen.3–6 The 
problem is further compounded by the fact that, tentatively speaking, 
it is estimated that one-third of the world’s population harbours 
Mycobacterium tuberculosis in some latent or dormant form and 
therefore is at risk of developing reactivation of the disease.7 
About 9 million new cases of TB occur each year, which includes 
people who are also infected with HIV/AIDS. The global case load is 
certainly rising and being driven upwards in sub-Saharan Africa by the 
spread of HIV/AIDS. One of the reasons for the persistent burden of 
TB is failure to address the principal risk factors.8 In 1991, the World 
Health Assembly set a target for 70% case finding of smear positive TB 
and 80% of those identified cases should complete anti-TB treatment.9 
The most dramatic increase in the number of reported cases has been 
in sub-Saharan Africa. Between 1984 and 1990, increases of 86%, 
140%, 154% and 180% were reported in Tanzania, Burundi, Zambia 
and Malawi respectively.10 The impact of HIV on TB prevalence is 
clearly seen with the increase in the prevalence of congenital TB, 
paucibacillary or smear-negative TB, extrapulmonary TB, reactivation 
and reinfection TB and immune reconstitution inflammatory syndrome 
(IRIS).11 It has been estimated that a billion people will be newly 
infected with Mycobacterium tuberculosis between 2002 and 2020, 
unless TB control is further strengthened. More than 150 million people 
will develop active disease and 36 million people will die.12
South Africa is a middle income country and is relatively well provided, 
with 143 laboratories performing sputum smears and 18 culture 
laboratories also capable of performing drug sensitivity testing.13
Tuberculosis is the most common notifiable disease in South Africa. 
It ranks second among the 22 high-burden TB countries in terms of 
TB incidence and seventh in terms of overall TB burden.14 The rate 
is equivalent to 29 cases of TB every hour, with 80% of the cases 
occurring in the 15 to 49 year age group, representing one of the 
highest rates in the world.15 
The seriousness of the epidemic was confirmed in June 1996, when 
the WHO declared that South Africa had one of the worst recorded 
TB epidemics in the world because of the rising rates of HIV and the 
emergence of multidrug resistant TB. The TB epidemic is largely a 
result of historical neglect, health service fragmentation and poor 
patient management, compounded by one of the fastest growing HIV 
epidemics ever recorded.15 In 1996, 86 221 TB cases were reported, 
18% of which interrupted their treatment and potentially spread the 
disease.16 In South Africa, 550 out of 100 000 have TB. The provinces 
affected the most are KwaZulu-Natal, the Western Cape, Eastern Cape 
and Gauteng, which have 80% of TB cases in South Africa. Of these, 
only 54% are cured and 13% of patients stop taking treatment.17  
   
In the Eastern Cape province there has been a dramatic increase 
in reported cases of pulmonary TB, from 10 358 in 1995 to 28 800 
in 1997. The incidence for 1997 was about 500 per 10 000.18 The 
provincial cure rate for all pulmonary TB cases in 1997 was 38.3%, 
with a treatment interruption rate of 21.9%.19 It represents a huge 
waste of money and an even greater cost in terms of morbidity and 
mortality.
This study was done at the Mbekweni Health Centre TB clinic, which 
is one of the four community health centres (CHC) in the King Sabata 
Dalindyebo health district. The objective of the study was to explore 
and describe the reasons why patients at Mbekweni Health Centre 
do not complete their TB treatment and the rationale was to make 
recommendations to improve treatment compliance. 
Methodology
A cross-sectional study was undertaken for which all TB patients who 
were registered at Mbekweni Health Centre for their treatment from 6 
August 2001 to 24 December 2003 were included. Demographic and 
treatment information was obtained from the GW 20 TB treatment 
blue cards, kept by the TB clinic. The sample size was 95 for a 
treatment interruption at an expected frequency of 50% with 95% 
confidence interval. Patients were informed of the study and verbal or 
written consent was obtained prior to participation. A health educator, 
nurses and field workers interviewed the participants either at the 
health centre or at the patient’s home. The participants had the option 
of being interviewed or of completing a questionnaire. During the 
interview, the opportunity was taken to counsel the patients about TB, 
the TB treatment course and possible complications of interrupting 
TB treatment. Approval for the study was obtained from the Ethics 
Committee of Walter Sisulu University, and permission was obtained 
from the District Health Manager and the Nursing Service Manager of 
Mbekweni Health Centre.  
Results
According to the records of the GW 20 TB blue cards, 255 patients 
were registered as pulmonary TB patients on treatment between 
6 August 2001 and 30 December 2003, and 121 (47.5%) of these 
patients did not complete their TB treatment which is shown in Figure 1. 
Only 61 of these patients who had interrupted their TB treatment could 
be traced. 
Figure 1: Distribution by treatment outcome
53%
47%
Those patients who were interviewed or completed the questionnaire 
themselves indicated various reasons for interrupting their TB 
treatment, e.g. no drugs at the clinic and no money to go to hospital 
(13.83%), too busy at work (3.46%), relative advised to stop treatment 
(3.46%), did not know the treatment course (5.17%), and clinic too far 
away (1.73%), while 8.62% provided no reasons. Out of 61 patients 
58 patients who interrupted their TB treatment answered the questions 
while 3 patients did not answer the question, which is shown in Table I.
Sixty of the patients were not interviewed as they were not at home 
at the time or had changed residence. The age of those who had 
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interrupted their treatment ranged from four to 75 years. The mean, 
mode and median age were 43.8 years, 60 years and 43 years 
respectively. There were 29 females and 31 males, and most of the 
interrupters were male in the age group 60 to 69 years. More than 
one-third (37.9%) of the patients were uneducated and 43.1% were 
educated only up to Standard 5. None had a tertiary education. Of the 
patients who interrupted their treatment, 81% were unemployed. 
With regard to the treatment regimen of the patients who had 
interrupted their treatment, 37 (66.6%) were new cases, 10 (20.4%) 
were being retreated and seven (13%) were treatment failures. 
Seven patients did not complete the questionnaire with regard to 
their treatment regimen. During the study it was observed that some 
patients had poor knowledge about the duration of TB treatment. One 
patient answered that the treatment course is only for five days, while 
two answered that it lasted three months and four months respectively. 
Thirty-four (56.6%) patients knew that the duration of TB treatment was 
six months, four patients said that the treatment lasted eight months, 
and 19 patients were totally ignorant of the duration of TB treatment.
There were different perceptions among the patients about interrupting 
treatment. Fourteen said they would fall ill again, 10 thought nothing 
would happen to them, five said they might infect others, seven had 
a fear of death, and two thought they could infect others and may 
die. Two said they would restart treatment, one said taking treatment 
without food might make them sick and since meals were often missed 
because of poverty, treatment was also frequently missed. Seventeen 
said they did not know the effect of treatment interruption. 
Among those who interrupted their treatment, 25 (40.9%) said that they 
at times had treatment support either from a family member or from a 
village health worker.
Discussion
All the TB patients in the target population might not have attended 
Mbekweni Health Centre for various reasons, thus we may have 
missed interviewing some of them because the study was confined to 
those patients who attended the health centre during the time frame of 
the study. At a time when there is a resurgence of TB, largely due to 
the HIV pandemic, this is an alarming rate of TB treatment interruption. 
In this situation, interrupting TB treatment is dangerous 
because of the risk of developing multidrug resistant (MDR) 
and extensively drug resistant (XDR) TB. The Eastern 
Cape is one of the poorest provinces in South Africa and 
because of its poverty, illiteracy, TB and HIV, this is a recipe 
for disaster.  
Regarding treatment interruption in other countries, the 
problem of non-compliance is frequent in Saudi Arabia 
and has serious implications. After their period of hospital 
admission, 456 out of 628 patients (56%) did not attend 
the first clinic visit. The retrieval system was successful in 
bringing back some of the patients, however, reducing the 
defaulter rate to only 13.2%.20 In a study done in Malawi 
in 1995, 11.5% of the respondents were registered as 
defaulters.21 A household-based survey in six randomly 
selected catchment areas of Ndola, Zambia established 
that 29.8% of TB patients failed to comply with the TB drug 
regimen once they started feeling better.22
Reasons Male (No) % Female (No) % Total (No) %
1 No treatment at clinic ( 1 )          1.73 ( 7 )            12.1  ( 8 )      13.83
2 I did not miss the treatment ( 2 )           3.44  ( 2 )         3.44
3 Side effects of drugs ( 1 )           1.73 ( 3 )           5.17 ( 4 )        6.90
4 No money to go to clinic ( 8 )         13.79 ( 1 )           1.73 ( 9 )      15.52
5 Too old / sick / nobody to collect treatment ( 2 )           3.44 ( 1 )           1.73 ( 3 )        5.17
6 Change of living place ( 6 )         10.34 ( 5 )           8.62 ( 11 )     18.96
7 Felt well and better ( 4 )           6.89 ( 4 )           6.89 ( 8 )      13.78
8 Busy at work ( 1 )           1.73 ( 1 )           1.73 ( 2 )        3.46
9
Relative told to stop TB 
treatment during pregnancy 
or as patient had no TB
( 1 )           1.73 ( 1 )           1.73 ( 2 )        3.46
10 Did not know the treatment course ( 3 )            5.17 ( 3 )        5.17
11 Clinic too far ( 1 )           1.73 ( 1 )        1.73
12 No reasons ( 4 )           6.89 ( 1 )            1.73 ( 5 )        8.62
Total 29        (50% ) 29         ( 50% ) 58       100%
Table I: Reasons for interrupting TB treatment according to gender.
South Africa faces one of the most devastating TB epidemics in the 
world. Nearly 48% of the defaulters were lost to follow-up during the 
time of the survey. A lack of family support was found to be a factor 
strongly predictive of defaulting.23 Our study revealed that most of 
the defaulters were in the 60 to 69 year age group and among the 
uneducated and unemployed. In South Africa, nurses at primary care 
level manage about 90% of TB patients. Despite efforts to improve 
the quality of care for these patients, many fail to complete their 
treatment as prescribed. Poor rapport between healthcare providers 
and TB patients is a major reason for non-adherence to treatment.24 
In this study, 42.6% of the patients responded that a doctor informed 
them that they had TB, 42.7% were informed by a nurse, 9.8% by 
the village health workers and 4.9% by others. In a study conducted 
in Hlabisa, South Africa in 1994 and 1995, 629 (17%) out of 3 610 
surviving patients failed to complete treatment. This had increased 
from 11% in 1991 to 22% in 1996.25 In a study conducted in the 
Eastern Cape in 2001, 13% of patients interrupted their TB treatment, 
while a study in the OR Tambo district municipality in 1999 and 2000 
found an interruption rate of 19%.26 The Vulindlela TB home-based 
care (HBC) project was started at Ntafufu Clinic in Port St Johns 
in February 2004. Before the project, 74% of TB patients did not 
complete the course of treatment. After volunteers began to support 
the patients, 81% completed the treatment successfully.26 In this study, 
47.5% of the patients interrupted their treatment. This was perhaps 
an indicator of poor follow-up of patients. As this is the first study 
of this nature at Mbekweni Health Centre, a follow-up study should 
be done after introducing the remedial measures. Uneducated and 
unemployed males aged between 60 and 69 years comprised the 
majority of defaulters. These groups will need special attention and 
measures in the future, along with the support of family members, 
health workers, TB field workers, community members, community 
leaders and the government during and after the treatment. In this 
study it was found that those who were poor and had to pay more than 
R6.00 in taxi fare to get to the health centre and back home formed the 
majority of defaulters. This was supported by the finding that 26.6% 
of the patients had no income at all, while 16.6% were earning less 
than R500.00 a month. This study answers some of the questions. 
Further study needs to be done to find out whether the patients were 
well informed and counselled by healthcare professionals about their 
disease, drugs, dose, duration of treatment, possible side effects of 
drugs, complications of disease, possible complications of treatment 
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interruption and follow-up dates. In this study it was found that 31.6% 
of the defaulters did not know the duration of treatment and 28.3% did 
not know the consequences of treatment interruption. This highlights 
poor communication and a lack of support during the treatment period. 
Fourteen per cent of the patients indicated that, at times, they could not 
get the treatment from the health centre. This represents a healthcare 
system failure. MDR and XDR TB result mainly from treatment that 
is inadequate in terms of dose, duration, inappropriate drug regimen, 
poor quality of drugs and poor compliance by the patients. Complete 
education of the patients about their disease, drugs, dose, treatment 
duration, importance of DOTS and treatment compliance is vital to 
improving the cure rate and to prevent MDR and XDR TB. It is difficult 
to achieve an 85% cure rate (WHO recommended target) without 
defaulter tracing and visits to the patients’ homes. Even though TB 
treatment policy and guidelines are in place, key indicators and targets 
have been identified, and registers and key monitoring tools have been 
developed, a lack of proper supervision of staff and health institutions 
and unmotivated, untrained and inadequate staff prevent the desired 
outcomes from being achieved. Patient overload in the health 
institution, delays in receiving or not receiving laboratory results and a 
poor supply of medicines, sputum jars and other necessary materials 
are some of the realities that act as obstacles to improving the cure 
rate. 
Conclusion
This study established an unacceptably high proportion of TB patients 
who interrupt their treatment for various reasons. The major reasons 
were change of living place, no money to go to the clinic, no treatment 
at the clinic, and that they felt well and better. Other reasons were side 
effects of the drugs, too old or too sick, did not know the treatment 
course, that the clinic was too far or that they were busy at work. Some 
of the patients interrupted their treatment without any reason. 
Recommendations
To improve the cure rate and treatment compliance rate, TB drugs 
and clinics should be easily accessible. Patients should be well 
informed about the disease and the drugs, e.g. dose and duration of 
treatment. They should be equipped with education and information 
about treatment compliance, possible side effects of the drugs, 
and the effects of treatment interruption, such as possible physical 
complications, treatment failure, multidrug resistant TB and extensively 
drug resistant TB. National TB treatment policy, protocol, guidelines, 
recording, reporting, monitoring and supervision should be a priority. 
There should be adequate staff, e.g. doctors, nurses and village 
health workers to treat the patients, as well as for follow up or for 
home visits as soon as the patients interrupt their treatment. Should 
the patients move to a new place, they should be advised to inform 
the clinic and get a transfer letter from the clinic to a nearby health 
institution to continue their treatment. Where illiteracy and poverty 
are high, as in the study setting, the idea of voluntary work does 
not solve the problem. There should be some incentive for the 
field workers and health workers so that they can cover their daily 
expenses. Home visits to all TB patients who interrupt their treatment 
are highly recommended. These visits would help with monitoring 
and supporting patients, with collection of sputum and with providing 
their monthly supply of medicine at their home. The visits would also 
help with tracing those who interrupt their treatment, thereby reducing 
the treatment interruption rate, treatment failure rate, cross-infection 
rate, and MDR and XDR TB, and with improving the TB cure rate and 
reducing the prevalence of TB in the country. Continuity and holistic 
care of all TB patients is recommended and should be practised.
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